<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of alloantibodies to platelets is a major problem in the supportive management of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We report here a case of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> refractory to platelet transfusion </plain></SENT>
<SENT sid="2" pm="."><plain>An <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi>, <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, which was used for the therapy of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, modulated <z:e sem="disease" ids="C0948201" disease_type="Disease or Syndrome" abbrv="">alloimmunization</z:e> to platelets in this patient, followed by repeated platelet transfusion </plain></SENT>
<SENT sid="3" pm="."><plain>The treatment reduced platelet alloantibodies detected by anti-human immunoglobulin lymphocytotoxicity test, with change of the CD4/CD8 ratio in T lymphocytes in peripheral blood </plain></SENT>
<SENT sid="4" pm="."><plain>These results suggest the usefulness of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> for the prevention of platelet <z:e sem="disease" ids="C0948201" disease_type="Disease or Syndrome" abbrv="">alloimmunization</z:e> </plain></SENT>
</text></document>